Back to today’s briefing

Story perspectives

U.S. Becomes Top Pharma Importer Amid Tariff Concerns

5/23/2025

36 3

Summary

Story summary

In 2024, the U.S. became the largest global importer of pharmaceuticals, totaling $213 billion.
Proposed tariffs seek to enhance domestic manufacturing but risk raising drug prices and disrupting supply chains.
Experts caution that tariffs could negatively affect biotech innovation and potentially cause drug shortages.
While companies like Eli Lilly are investing in U.S. production, the long-term effects of tariffs remain uncertain.

1 of 1

Story summary

In 2024, the U.S. became the largest global importer of pharmaceuticals, totaling $213 billion.
Proposed tariffs seek to enhance domestic manufacturing but risk raising drug prices and disrupting supply chains.
Experts caution that tariffs could negatively affect biotech innovation and potentially cause drug shortages.
While companies like Eli Lilly are investing in U.S. production, the long-term effects of tariffs remain uncertain.